FDA posts a new batch of warning letters to online peptide sellers

The U.S. Food and Drug Administration has issued another round of warning letters to online peptide sellers, targeting five websites that listed retatrutide, semaglutide, tirzepatide, elamipretide and tesamorelin, along with bacteriostatic water used to reconstitute powdered drugs ^[1]. Some of the companies marketed their products as "research use" chemicals, but all five were cited for selling unapproved drugs ^[1].

The letters, posted by the agency in late August 2026, follow a pattern that has become routine over the past two years: sites sell vials of powder with no FDA approval, no prescription requirement and disclaimers saying the material is not for human use. Regulators have repeatedly treated those disclaimers as insufficient when the products are marketed in ways that point toward human weight-loss or performance use ^[1].

The scale of the enforcement push

These five letters are a small piece of a much larger campaign. The Partnership for Safe Medicines, a nonprofit that tracks drug-supply enforcement, says it has counted 160 FDA warning letters to telehealth companies and compounders, plus 50 state pharmacy board actions against unsafe compounders ^[1]. The group identified 55 FDA warning letters to GLP-1 compounders in the first half of 2026 alone ^[1].

Retatrutide is drawing particular attention. It is an experimental Eli Lilly weight-loss drug that has not been approved anywhere, which means there is no legitimate commercial supply chain for it. Any version obtained outside a Lilly program is considered a black-market product ^[1]. Lilly has said compounded retatrutide is illegal ^[1]. Physicians quoted by The Guardian said they see scientific promise in the drug but warned patients away from unregulated sources, with one plastic surgeon saying of people buying it on the black market, "who knows what… they are taking" ^[1].

The harms are not hypothetical. Doctors in the UK told the BBC that young, fit patients are showing up in hospitals, some with kidney failure, as illicit retatrutide supply has expanded there ^[1]. A 20-year-old gym-goer who ordered "retatrutide" from a Chinese supplier accidentally took eight times the recommended dose and described the nausea and diarrhea as "horrendous" ^[1].

What the science says about peptides generally

A UCLA Health review of 565 studies on six popular unapproved peptides — BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu — found little evidence of meaningful benefit ^[1]. More than two-thirds of the studies were done only in animals, and the human research that existed was generally low quality ^[1]. The reviewers flagged safety problems, including an MK-677 trial halted over congestive heart failure risk, and warned that unregulated products may contain undisclosed or dangerous substances ^[1]. Their conclusion was that marketing has outpaced the medicine ^[1].

There is also a supply-chain concern. Blockchain analytics firms Chainalysis and TRM Labs have reported that China-based chemical companies that made fentanyl precursors have moved into the peptide business, in some cases while continuing to sell precursors to drug cartels ^[1].

Why it matters for patients

Products sold as "research use only" peptides sit entirely outside the system that verifies what is in a vial. There is no FDA review of identity, purity, sterility or dose, and no manufacturer accountability if something goes wrong. That is the core of the FDA's position: the label on the box does not change what the product legally is ^[1].

For people comparing costs, the gap between an approved semaglutide or tirzepatide product and a gray-market vial can look large. The tradeoff is that dosing errors are easy to make with powders that must be mixed, as the BBC case illustrates ^[1], and the contents may not match the label at all ^[1].

What happens next

Warning letters typically require a written response from the company, but the recipients' names, the specific deadlines and whether any of these products were laboratory-tested are not stated in the available reporting. Enforcement experts have argued that state pharmacy boards should also investigate illegal sellers, issue public warnings and coordinate with attorneys general and law enforcement ^[1]. Whether that happens in response to this batch is not yet known.